Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy

被引:231
作者
Lehky, RJ
Leonard, GD
Wilson, RH
Grem, JL
Floeter, MK
机构
[1] Natl Naval Med Res Inst, Dept Neurol, Bethesda, MD 20889 USA
[2] NINDS, Electromyog Sect, Bethesda, MD 20892 USA
[3] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[4] Queens Univ Belfast, Belfast, Antrim, North Ireland
关键词
drug-induced neuropathy neuromyotonia; neurotoxicity; oxatolatin; SNAPs;
D O I
10.1002/mus.10559
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oxaliplatin, a platinum-based chemotherapeutic agent, is effective in the treatment of solid tumors, particularly colorectal cancer. During and immediately following oxaliplatin infusion, patients may experience cold-induced paresthesias, throat and jaw tightness, and occasionally focal weakness. We assessed nerve conduction studies and findings on needle electromyography of patients with metastatic colorectal cancer before and during treatment with oxaliplatin. Twenty-two patients had follow-up studies within 48 h following oxaliplatin infusions, and 14 patients had follow-up studies after 3-9 treatment cycles. Repetitive compound muscle action potentials and neuromyotonic discharges were observed in the first 24-48 h following oxaliplatin infusion, but resolved by 3 weeks. After 8-9 treatment cycles, sensory nerve action potential amplitudes declined, without conduction velocity changes or neuromyotonic discharges. The acute neurological symptoms reflect a state of peripheral nerve hyperexcitability that likely represents a transient oxaliplatin-induced channelopathy. Chronic treatment causes an axonal neuropathy similar to other platinum-based chemotherapeutic agents.
引用
收藏
页码:387 / 392
页数:6
相关论文
共 40 条
[1]   The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons [J].
Adelsberger, H ;
Quasthoff, S ;
Grosskreutz, J ;
Lepier, A ;
Eckel, F ;
Lersch, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (01) :25-32
[2]   CISPLATIN-ASSOCIATED NEUROTOXICITY - CAN IT BE PREVENTED [J].
ALBERTS, DS ;
NOEL, JK .
ANTI-CANCER DRUGS, 1995, 6 (03) :369-383
[3]   AAEM MINIMONOGRAPH NUMBER-44 - DISEASES ASSOCIATED WITH EXCESS MOTOR UNIT-ACTIVITY [J].
AUGER, RG .
MUSCLE & NERVE, 1994, 17 (11) :1250-1263
[4]  
Baker Danial E, 2003, Rev Gastroenterol Disord, V3, P31
[5]   Neurological potassium channelopathies [J].
Benatar, M .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2000, 93 (12) :787-797
[6]   Oxaliplatin-related side effects: Characteristics and management [J].
Cassidy, J ;
Misset, JL .
SEMINARS IN ONCOLOGY, 2002, 29 (05) :11-20
[7]  
deCarvalho M, 1996, J NEUROL, V243, P614
[8]   Prevention of oxaliplatin-induced neuropathy by carbamazepine: A pilot study [J].
Eckel, F ;
Schmelz, R ;
Adelsberger, H ;
Erdmann, J ;
Quasthoff, S ;
Lersch, C .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (03) :78-82
[9]   Pharmacokinetics of oxaliplatin in humans [J].
Ehrsson, H ;
Wallin, I ;
Yachnin, J .
MEDICAL ONCOLOGY, 2002, 19 (04) :261-265
[10]   PHASE-I STUDY OF OXALIPLATIN IN PATIENTS WITH ADVANCED CANCER [J].
EXTRA, JM ;
ESPIE, M ;
CALVO, F ;
FERME, C ;
MIGNOT, L ;
MARTY, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (04) :299-303